COMMUNIQUÉS West-GlobeNewswire

Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

22/02/2024 - 14:00

REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

22/02/2024 - 14:00

FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today [...]

BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

22/02/2024 - 14:00

LAS VEGAS, NV, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading manufacturer and distributor of innovative, all-natural dietary supplements, announces the development on an [...]

MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence

22/02/2024 - 14:00

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is pleased to announce that the Limmi Disease Insights Platform is now [...]

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

22/02/2024 - 14:00

TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. ( [...]

Notable Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment

22/02/2024 - 14:00

Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk, time, and cost of drug development Volasertib Phase 2 trial initiation in relapsed/ [...]

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

22/02/2024 - 14:00

TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S [...]

American College of Medical Genetics and Genomics Includes OGM in Latest Edition of Technical Laboratory Standards for Solid Tumor Analysis

22/02/2024 - 14:00

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) was included for the first time in the American College of Medical Genetics and [...]

Apnimed to Participate in the Upcoming Evercore ISI 2024 Emerging Biotech Conference

22/02/2024 - 14:00

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and [...]

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

22/02/2024 - 14:00

Company implementing a series of cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data from the ongoing Phase 1/2 [...]

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury

22/02/2024 - 13:53

SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune ™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company [...]

ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option

22/02/2024 - 13:47

Neurological diseases, which affect up to 16 million people over 18 years old in the US, are the leading cause of physical and cognitive disability. A growing body of evidence supports that activation of more than one [...]

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

22/02/2024 - 13:32

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and [...]

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

22/02/2024 - 13:31

BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development [...]

Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update

22/02/2024 - 13:30

Full year 2023 total revenues of $464.4 million , compared to $250.3 million in 2022 Full year 2023 CAPLYTA net product sales were $462.2 million , representing year-over-year growth of 86% . CAPLYTA fourth quarter 2023 [...]

Venus Concept Announces CE Mark for Venus Versa Pro in Europe

22/02/2024 - 13:30

TORONTO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received the CE Mark from DEKRA [...]

Kura Oncology to Participate in Three Upcoming Investor Conferences

22/02/2024 - 13:30

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

22/02/2024 - 13:30

WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration (FDA) Granted Priority [...]

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

22/02/2024 - 13:30

Industry Leader and Retina Expert, Pravin U. Dugel, MD, Becomes Executive Chair Jeffrey S. Heier, MD to become Chief Scientific Officer, Peter K. Kaiser, MD to be Medical Director, and Sanjay Nayak, MBBS, PhD to become [...]